Literature DB >> 21206575

Csf amines and their metabolites in first episode drug naive schizophrenic patients and their correlations with dimensions of schizophrenia.

I Anand1, T A Sunitha, Sumant Khanna.   

Abstract

There has been great interest in the neurobiological substrate of the different dimensions of schizophrenia. This has largely focused on structural and functional changes while it has been acknowledged that there is a relation between pharmacological response and neurotransmitter alteration on these dimensions. Atypical anti psychotics which affect both positive and negative symptoms mediate their action predominantly through dopaminergic and serotonergic receptors. The current study extends this further looking at CSF amines. 37 drug naive first episode psychosis patients with the duration of illness less than 2 years were included. Patients were assessed with SAPS (Scale for Assessment of Positive Symptoms) and SANS (Scale for Assessment of Negative Symptoms). Lumbar puncture was done under sterile conditions and CSF was analyzed by HPLC for dopamine, serotonin and their metabolites. Mean CSF 5- HIAA was 25.35ng/dl. Mean CSF 5 HT was 7.72 ng/dl. Mean CSFHVA was 36.99 ng/dl. Mean CSF 5-DA was 3.06 ng/dl. There was significant positive correlation between CSF5-HIAA and Negative and Disorganization dimensions. There was significant negative correlation between CSF HVA and Psychosis dimension. There is evidence to support that the implication of serotonin in Negative and Disorganization dimensions and the Serotonin- Dopamine interaction and dimensions of schizophrenia.

Entities:  

Keywords:  Dopamine; Schizophrenia; Serotonin

Year:  2002        PMID: 21206575      PMCID: PMC2954391     

Source DB:  PubMed          Journal:  Indian J Psychiatry        ISSN: 0019-5545            Impact factor:   1.759


  11 in total

Review 1.  Molecular pathology of schizophrenia: more than one disease process?

Authors:  T J Crow
Journal:  Br Med J       Date:  1980-01-12

2.  Rapid, concurrent analysis of dopamine, 5-hydroxytryptamine, their precursors and metabolites utilizing high performance liquid chromatography with electrochemical detection: analysis of brain tissue and cerebrospinal fluid.

Authors:  J A Nielsen; C A Johnston
Journal:  Life Sci       Date:  1982-12-20       Impact factor: 5.037

3.  Regional differences in homovanillic acid concentrations after acute and chronic administration of antipsychotic drugs.

Authors:  M G Bowers; A Rozitis
Journal:  J Pharm Pharmacol       Date:  1974-09       Impact factor: 3.765

4.  Negative symptoms in schizophrenia. Definition and reliability.

Authors:  N C Andreasen
Journal:  Arch Gen Psychiatry       Date:  1982-07

5.  Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia.

Authors:  D Pickar; A Breier; J K Hsiao; A R Doran; O M Wolkowitz; C N Pato; P E Konicki; W Z Potter
Journal:  Arch Gen Psychiatry       Date:  1990-07

6.  5-HIAA in cerebrospinal fluid and deficit schizophrenic characteristics.

Authors:  J G Csernansky; R J King; W O Faustman; J A Moses; M E Poscher; K F Faull
Journal:  Br J Psychiatry       Date:  1990-04       Impact factor: 9.319

7.  CSF amine metabolites, clinical symptoms, and body movement in psychiatric patients.

Authors:  L Kirstein; M B Bowers; G Heninger
Journal:  Biol Psychiatry       Date:  1976-08       Impact factor: 13.382

8.  Low HVA and normal 5HIAA CSF levels in drug-free schizophrenic patients compared to healthy volunteers: correlations to symptomatology and family history.

Authors:  L H Lindström
Journal:  Psychiatry Res       Date:  1985-04       Impact factor: 3.222

9.  Symptoms of schizophrenia. Methods, meanings, and mechanisms.

Authors:  N C Andreasen; S Arndt; R Alliger; D Miller; M Flaum
Journal:  Arch Gen Psychiatry       Date:  1995-05

10.  The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy.

Authors:  P F Liddle
Journal:  Br J Psychiatry       Date:  1987-08       Impact factor: 9.319

View more
  2 in total

1.  An overview of Indian research in schizophrenia.

Authors:  Parmanand Kulhara; Ruchita Shah; K R Aarya
Journal:  Indian J Psychiatry       Date:  2010-01       Impact factor: 1.759

2.  Initiatives in biological research in Indian psychiatry.

Authors:  Amresh Shrivatava
Journal:  Indian J Psychiatry       Date:  2010-01       Impact factor: 1.759

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.